Non-hematopoietic erythropoietin-derived peptides for atheroprotection and treatment of cardiovascular diseases
Relevance: Cardiovascular diseases continue to be the leading cause of premature adult death. Lipid profile and atherogenesis: Dislipidaemia leads to subsequent lipid accumulation and migration of immunocompetent cells into the vessel intima. Macrophages accumulate cholesterol formi...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Belgorod National Research University
2020-09-01
|
| Series: | Research Results in Pharmacology |
| Online Access: | https://rrpharmacology.pensoft.net/article/58891/download/pdf/ |
| _version_ | 1797429469788504064 |
|---|---|
| author | Veronika S. Belyaeva Yulia V. Stepenko Igor I. Lyubimov Alexandr L. Kulikov Alesia A. Tietze Indira S. Kochkarova Olga V. Martynova Olga N. Pokopeyko Liliya A. Krupen’kina Andrey S. Nagikh Vladimir M. Pokrovskiy Evgeniy A. Patrakhanov Anastasia V. Belashova Petr R. Lebedev Anastasia V. Gureeva |
| author_facet | Veronika S. Belyaeva Yulia V. Stepenko Igor I. Lyubimov Alexandr L. Kulikov Alesia A. Tietze Indira S. Kochkarova Olga V. Martynova Olga N. Pokopeyko Liliya A. Krupen’kina Andrey S. Nagikh Vladimir M. Pokrovskiy Evgeniy A. Patrakhanov Anastasia V. Belashova Petr R. Lebedev Anastasia V. Gureeva |
| author_sort | Veronika S. Belyaeva |
| collection | DOAJ |
| description | Relevance: Cardiovascular diseases continue to be the leading cause of premature adult death. Lipid profile and atherogenesis: Dislipidaemia leads to subsequent lipid accumulation and migration of immunocompetent cells into the vessel intima. Macrophages accumulate cholesterol forming foam cells – the morphological substrate of atherosclerosis in its initial stage. Inflammation and atherogenesis: Pro-inflammatory factors provoke oxidative stress, vascular wall damage and foam cells formation. Endothelial and mitochondrial dysfunction in the development of atherosclerosis: Endothelial mitochondria are some of the organelles most sensitive to oxidative stress. Damaged mitochondria produce excess superoxide and H2O2, which are the main factors of intracellular damage, further increasing endothelial dysfunction. Short non-hematopoietic erythropoietin-based peptides as innovative atheroprotectors: Research in recent decades has shown that erythropoietin has a high cytoprotective activity, which is mainly associated with exposure to the mitochondrial link and has been confirmed in various experimental models. There is also a short-chain derivative, the 11-amino acid pyroglutamate helix B surface peptide (PHBSP), which selectively binds to the erythropoietin heterodymic receptor and reproduces its cytoprotective properties. This indicates the promising use of short-chain derivatives of erythropoietin for the treatment and prevention of atherosclerotic vascular injury. In the future, it is planned to study the PHBSP derivatives, the modification of which consists in adding RGD and PGP tripeptides with antiaggregant properties to the original 11-member peptide. |
| first_indexed | 2024-03-09T09:14:35Z |
| format | Article |
| id | doaj.art-246eb5a23e064d7fa0dfdd42e17e8c70 |
| institution | Directory Open Access Journal |
| issn | 2658-381X |
| language | English |
| last_indexed | 2024-03-09T09:14:35Z |
| publishDate | 2020-09-01 |
| publisher | Belgorod National Research University |
| record_format | Article |
| series | Research Results in Pharmacology |
| spelling | doaj.art-246eb5a23e064d7fa0dfdd42e17e8c702023-12-02T07:32:27ZengBelgorod National Research UniversityResearch Results in Pharmacology2658-381X2020-09-0163758610.3897/rrpharmacology.6.5889158891Non-hematopoietic erythropoietin-derived peptides for atheroprotection and treatment of cardiovascular diseasesVeronika S. Belyaeva0Yulia V. Stepenko1Igor I. Lyubimov2Alexandr L. Kulikov3Alesia A. Tietze4Indira S. Kochkarova5Olga V. Martynova6Olga N. Pokopeyko7Liliya A. Krupen’kina8Andrey S. Nagikh9Vladimir M. Pokrovskiy10Evgeniy A. Patrakhanov11Anastasia V. Belashova12Petr R. Lebedev13Anastasia V. Gureeva14Belgorod State National Research UniversityBelgorod State National Research UniversityGurus BioPharm LLCBelgorod State National Research UniversityUniversity of GothenburgBelgorod State National Research UniversityBelgorod State National UniversitySechenov UniversityBelgorod State National Research UniversityBelgorod State National Research UniversityBelgorod State National Research UniversityBelgorod State National Research UniversityBelgorod State National Research UniversityBelgorod State National Research UniversityKursk State Medical UniversityRelevance: Cardiovascular diseases continue to be the leading cause of premature adult death. Lipid profile and atherogenesis: Dislipidaemia leads to subsequent lipid accumulation and migration of immunocompetent cells into the vessel intima. Macrophages accumulate cholesterol forming foam cells – the morphological substrate of atherosclerosis in its initial stage. Inflammation and atherogenesis: Pro-inflammatory factors provoke oxidative stress, vascular wall damage and foam cells formation. Endothelial and mitochondrial dysfunction in the development of atherosclerosis: Endothelial mitochondria are some of the organelles most sensitive to oxidative stress. Damaged mitochondria produce excess superoxide and H2O2, which are the main factors of intracellular damage, further increasing endothelial dysfunction. Short non-hematopoietic erythropoietin-based peptides as innovative atheroprotectors: Research in recent decades has shown that erythropoietin has a high cytoprotective activity, which is mainly associated with exposure to the mitochondrial link and has been confirmed in various experimental models. There is also a short-chain derivative, the 11-amino acid pyroglutamate helix B surface peptide (PHBSP), which selectively binds to the erythropoietin heterodymic receptor and reproduces its cytoprotective properties. This indicates the promising use of short-chain derivatives of erythropoietin for the treatment and prevention of atherosclerotic vascular injury. In the future, it is planned to study the PHBSP derivatives, the modification of which consists in adding RGD and PGP tripeptides with antiaggregant properties to the original 11-member peptide.https://rrpharmacology.pensoft.net/article/58891/download/pdf/ |
| spellingShingle | Veronika S. Belyaeva Yulia V. Stepenko Igor I. Lyubimov Alexandr L. Kulikov Alesia A. Tietze Indira S. Kochkarova Olga V. Martynova Olga N. Pokopeyko Liliya A. Krupen’kina Andrey S. Nagikh Vladimir M. Pokrovskiy Evgeniy A. Patrakhanov Anastasia V. Belashova Petr R. Lebedev Anastasia V. Gureeva Non-hematopoietic erythropoietin-derived peptides for atheroprotection and treatment of cardiovascular diseases Research Results in Pharmacology |
| title | Non-hematopoietic erythropoietin-derived peptides for atheroprotection and treatment of cardiovascular diseases |
| title_full | Non-hematopoietic erythropoietin-derived peptides for atheroprotection and treatment of cardiovascular diseases |
| title_fullStr | Non-hematopoietic erythropoietin-derived peptides for atheroprotection and treatment of cardiovascular diseases |
| title_full_unstemmed | Non-hematopoietic erythropoietin-derived peptides for atheroprotection and treatment of cardiovascular diseases |
| title_short | Non-hematopoietic erythropoietin-derived peptides for atheroprotection and treatment of cardiovascular diseases |
| title_sort | non hematopoietic erythropoietin derived peptides for atheroprotection and treatment of cardiovascular diseases |
| url | https://rrpharmacology.pensoft.net/article/58891/download/pdf/ |
| work_keys_str_mv | AT veronikasbelyaeva nonhematopoieticerythropoietinderivedpeptidesforatheroprotectionandtreatmentofcardiovasculardiseases AT yuliavstepenko nonhematopoieticerythropoietinderivedpeptidesforatheroprotectionandtreatmentofcardiovasculardiseases AT igorilyubimov nonhematopoieticerythropoietinderivedpeptidesforatheroprotectionandtreatmentofcardiovasculardiseases AT alexandrlkulikov nonhematopoieticerythropoietinderivedpeptidesforatheroprotectionandtreatmentofcardiovasculardiseases AT alesiaatietze nonhematopoieticerythropoietinderivedpeptidesforatheroprotectionandtreatmentofcardiovasculardiseases AT indiraskochkarova nonhematopoieticerythropoietinderivedpeptidesforatheroprotectionandtreatmentofcardiovasculardiseases AT olgavmartynova nonhematopoieticerythropoietinderivedpeptidesforatheroprotectionandtreatmentofcardiovasculardiseases AT olganpokopeyko nonhematopoieticerythropoietinderivedpeptidesforatheroprotectionandtreatmentofcardiovasculardiseases AT liliyaakrupenkina nonhematopoieticerythropoietinderivedpeptidesforatheroprotectionandtreatmentofcardiovasculardiseases AT andreysnagikh nonhematopoieticerythropoietinderivedpeptidesforatheroprotectionandtreatmentofcardiovasculardiseases AT vladimirmpokrovskiy nonhematopoieticerythropoietinderivedpeptidesforatheroprotectionandtreatmentofcardiovasculardiseases AT evgeniyapatrakhanov nonhematopoieticerythropoietinderivedpeptidesforatheroprotectionandtreatmentofcardiovasculardiseases AT anastasiavbelashova nonhematopoieticerythropoietinderivedpeptidesforatheroprotectionandtreatmentofcardiovasculardiseases AT petrrlebedev nonhematopoieticerythropoietinderivedpeptidesforatheroprotectionandtreatmentofcardiovasculardiseases AT anastasiavgureeva nonhematopoieticerythropoietinderivedpeptidesforatheroprotectionandtreatmentofcardiovasculardiseases |